News archive 2015
MnM Conference on Neuroscience R&D, Barcelona
December, 3-4th 2015
Meet NeuroProof CEO Olaf Schröder at the MnM conference and discuss the presentation and latest NeuroProof assays. See publications.
Further information: www.mnmconferences.com/neuroscience-r-and-d-technologies-conference.html
NeuroProof at Axiogenesis Meeting in Cologne
November 25-27th 2015
NeuroProof Project Manager Dr. Benjamin Bader presented the latest results on functional phenotypic modeling of neuro-degenerative diseases using human iPSC-derived neurons and their comparison to well-known primary cell cultures growing on micro-electrode arrays. The topics presented include Parkinson's disease and seizure liability. See publications.
INGESTEM international congress
Paris, November 19-20th 2015
Meet us at the Society for Neuroscience Meeting 2015
October 17-21, in Chicago at booth #564
NeuroProof will present its new developments of functional and phenotypic in vitro assays with neuronal cell cultures on microelectrode arrays. We show new results on Poster presentations with human iPSC-derived neuronal cell cultures, applications in safety pharmacology (epilepsy) and our new Parkinson’s Disease assay. We look forward to discussing at the poster with you - You will find us here:
- Sat, Oct 17, 1:00 - 5:00 PM, 53.24/H21
A functional phenotypic screening In vitro assay for novel Parkinson’s drugs - comparing effects of human iPSC-derived dopaminergic neuronal networks and primary mouse midbrain cultures
B. M. Bader, A.-M. Pielka, C. Ehnert, K. Jügelt, A. Gramowski-Voss, O. H.-U. Schroeder.
- Sun, Oct 18, 8:00 AM - 12:00 PM, 117.20/A41
Functional Maturation of neuronal networks In vitro is accelerated by combination of bioactive whey protein, natural bovine complex lipids and DHA
B. M. Bader, C. Kuang, C. Ehnert, K. Jügelt, A. Gramowski-Voss, Y. Xiao, R. McMahon, O. H.-U. Schroeder, D. Hondmann
- Tue, Oct 20, 8:00 AM - 12:00 PM, 497.05/H17
Prediction of drug-induced seizure-liability in human iPSC-derived neuronal networks compared to primary mouse networks - functional, phenotypic In vitro assessment using micro-electrode arrays.
A. Gramowski-Voss, A.-M. Pielka, C. Ehnert, K. Jügelt, O. H.-U. Schroeder, B. M. Bader.
- Tue, Oct 20, 8:00 AM - 12:00 PM, 497.04/H16
An In vitro epileptogenesis mouse model for anticonvulsant drug screening
C. Ehnert, A. Gramowki-Voss, B. M. Bader, O. H.-U. Schroeder
- Wed, Oct 21, 1:00 – 5:00 PM, 760.04/B29
Increasing functional complexity and maturity of human iPSC-derived neuronal networks In vitro by glia co-culture and mixing different neuronal populations
A.-M. Pielka, A. Voss, C. Ehnert, K. Jügelt, O. H.-U. Schroeder, B. M. Bader.
You will find PDFs of our current posters on our Downloads page.
NeuroProof presents Parkinson’s prevention assay
NeuroProof presents its novel Parkinson’s prevention assay at the 25th Annual Conference of the German Society for Cytometry, October 7-9th, 2015. The work will be presented by Prof. em. Dieter G. Weiss, one of the co-founders of NeuroProof.
Here, we present the use of human iPSC-derived dopaminergic neurons as a functional phenotypic in vitro model system for screening novel Parkinson's relevant compounds. This functional assay adds to the NeuroProof strategy to screen compounds aiming to treat early patho-physiologies.
NeuroProof at the ISSCR 2015 in Stockholm, June 24-27th 2015
NeuroProof presents its iPSC-based Parkinson’s disease assay with a poster, poster board number W-1318, on Wednesday 24th of June from 18:30-20:30. The poster will be presented by Benjamin Bader who was responsible for development of this assay (download poster).
The aim of this development was to use human iPSC-derived neuronal networks containing dopaminergic neurons growing on micro-electrode arrays (MEAs) for the functional validation of phenotypic in vitro screening Parkinson's (PD) relevant compounds.
With this assay NeuroProof paves the way to screen compounds to treat early patho-physiologies of this disease. It is possible to monitor a compounds effect to prevent or rescue Parkinson’s like functional disturbances.
NeuroProof and Mead Johnson present novel in vitro assay for testing natural products
ESPGHAN meeting in Amsterdam, May 6-9th 2015
NeuroProof collaborates with Mead Johnson Nutrition to study the effects of natural products such as omega-3 fatty acid DHA on brain function and excitation. We present a novel assay using MEAs to identify compound combinations which are beneficial for functional neuronal development.
At our poster titled "Combination of DHA with bioctive whey protein, natural bovine complex lipids accelerates functional maturation of neuronal networks in vitro" (PO-N-0365, Abstract online in Abstract book) we present the results of functional phenotypic in vitro testing of natural products such as omega-3 fatty acid DHA and combination using the MEA technology and multi-parametric data analysis. At the 48th Annual meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition we show for the first time that natural products significantly accelerate early neuronal maturation in vitro. Our current research explores whether these findings translate into functional benefits in vivo.
NeuroProof at the Axiogenesis User Group Meeting in Cologne, April 15-17th 2015
NeuroProof presented the latest results on the functional evaluation of human iPSC-derived dopaminergic neurons (Dopa.4U, Axiogenesis) growing on micro-electrode arrays (see stem cell characterization info sheet).
"Using Dopa.4U neurons, we have added another assay to our Parkinson screening service. We now have shown the similarities and differences between mouse primary neurons and human iPSC-derived neurons." Dr. Bader said after the presentation. Thus, NeuroProof's aim to transfer the primary mouse in vitro MPP+ model to human iPSC-derived neurons was successful. Our customers can now compare compound efficacies on human and mouse cultures to observe species-dependent specificities for the screening of Parkinson's drugs.
AD/PD meeting in Vienna
March 28, 2017
Meet NeuroProof at the Annual Meeting for Alzheimers and Parkinson's Disease AD/PD 2017 in Vienna and discuss our newest functional assay for screening Alzheimer drugs on a human genetic APP-mutant cell culture model with Benjamin Bader at the poster on Thursday. We also present a new approach for comparing functional phenotypic effects of alpha-synuclein on mouse and human dopaminergic neurons. Visit the AD/PD website for the abstract:
Stem cells in drug discovery
March, 6-7th 2016, Cambridge
Meet NeuroProof Project Manager Benjamin Bader at the Conference on Advances in Drug Discovery and discuss the latest NeuroProof assays for functional phenotypic CNS drug discovery using human stem cells.
2nd Annual Conference on Neuroscience R&D Technologies
September, 29-30th 2016, London
Meet NeuroProof CEO Olaf Schröder at the 2nd Annual Conference on Neuroscience R&D Technologies conference and discuss the presentation and latest NeuroProof assays for functional phenotypic CNS drug discovery.
NeuroProof at Axiogenesis Meeting in Cologne
September 7-9th 2016
NeuroProof project manager Dr. Benjamin Bader presented the latest results on functional phenotypic modeling of neuro-degenerative diseases using human iPSC-derived neurons and their comparison to well-known primary cell cultures growing on micro-electrode arrays. The topics presented include effects of alpha-synuclein and botulinum toxin on hIPSC derived neuronal networks.
MEA meeting 2016
Reutlingen, June 28th - July 1st
ISSCR stem cell meeting
San Francisco, 22-26.6.2016
If you are attending the ISSCR meeting in San Francisco, come visit our two NeuroProof contributions: 1) The poster by Nagel et al. about functional evaluation of Axol's patient-derived iPSC neurons carrying a presinilin-1 mutation presented by Naomi Wessel-Carpenter and 2) the poster by Bader et al. about multi-parametrically characterizing the functional in vitro phenotype of Axiogensis' different "4U" neuron series with data on seizurogenic compounds and on our novel phenotypic readout used for phenotypic in vitro disease modeling (here Parkinson) which is presented by Elena Kfoury.
World Preclinical Congress
NeuroProof and Axiogenesis present a poster about " Monitoring and adapting the functional phenotypic of developing human iPSC-derived neuronal networks using multi-variate analysis of MEA data". Visit out poster and discuss the latest developments in multi-parametric data analysis for phenotypic screening of human iPSC-derived neurons.
Channelopathy Meeting 2016
Meet Alexandre Fouassier in Paris who presents some of our work on modulating neuronal receptors in human iPSC-derived neurons.
Ono Pharmaceuticals and NeuroProof at the 31st International Conference of Alzheimer's Disease International (ADI)
21-24 April 2016, Budapest
Ono Pharmaceuticals and NeuroProof co-presented novel functional in vitro results on the electrophysiological Characterization of GABA-A alpha5 negative allosteric modulators in hippocampal neurons and their efficacy to rescue amyloid beta-induced effects compared to standard of care and known pro-cognitive agents. See "Publications" for more information.
High Content & Phenotypic Screening 2016
Cambridge, UK. 10.05.2016
NeuroProof and Axiogenesis present newest results on how to "shift and rescue functional phenotypes for in vitro disease modeling – linking human iPSC-derived dopaminergic neurons with multi-parametric analysis of electrophysiological MEA data.” We show how the midbrain-like functional phenotype of human iPSC dopaminergic neurons is affected by Parkinson-related toxins and how this can be rescued in vitro. Looking forward to getting your comments and questions.